Potentiation of drug response

Abstract

The power of citalopram, fluvoxamine and paroxetine to increase the availability of sarotonin, norepinephrine and dopamine, particularly serotonin, is augmented by administration in combination with a drug which is a serotonin 1A receptor antagonist.

Claims

What is claimed is: 1. A method for potentiating the action of paroxetine in increasing the availability of serotonin, norepinephrine and dopamine in the brain, comprising administering paroxetine to a patient in need thereof in combination with WAY 100635. 2. A method for potentiating the action of paroxetine in increasing the availability of serotonin, norepinephrine and dopamine in the brain, comprising administering paroxetine to a petient in need thereof in combination with WAY 100635 wherein WAY 100635 is administered in a manner which provides a substantially constant blood level of WAY 100635, which level is sufficient to provide a substantially constant degree of potentiation of the action of paroxetine. 3. A method of treating a pathological condition which is created by or is dependent upon decreased availability of serotonin, norepinephrine or dopamine, which comprises administering to a patient in need of such treatment, paroxetine in combination with WAY 100635. 4. A method according to claim 3 wherein the pathological condition is depression. 5. A pharmaceutical composition which comprises paroxetine in combination with WAY 100635.
CROSS REFERENCE This application is a continuation-in-part of application Ser. No. 08/345,672, filed Nov. 28, 1994, now abandoned. FIELD OF THE INVENTION The present invention belongs to the fields of pharmacology, medicine and medicinal chemistry, and provides a method and compositions for increasing the availability of serotonin, norepinephrine and dopamine in the brain of patients to whom is administered citalopram, fluvoxamine or paroxetine. BACKGROUND OF THE INVENTION Over the past twenty years or more, the science of pharmacology has been particularly interested in the physiology of the neurons containing monoamines in the human brain. Discovery has followed discovery in the field and it has now been demonstrated that serotonin, norepinephrine and dopamine interact with a great number of receptors in the brain and control or affect processes which regulate many bodily organs and functions. Serotonin, particularly, has been found to be the key to a large number of processes which reveal themselves in both physiological and psychological functions. Perhaps the most dramatic discovery in medicinal chemistry in the recent past are the serotonin reuptake inhibitors, which are extremely effective in the treatment of depression. They increase the availability of serotonin in the synapse by reducing the uptake of serotonin by the serotonin uptake carrier. Dysfunction of the serotonin neurons resulting from excessive uptake results in depression, as well as other pathologies of the central nervous system. Not only are these drugs spectacularly effective in depression, they are also effective in treating numerous other conditions. Among the serotonin reuptake inhibitors are citalopram, fluvoxamine and paroxetine. While the primary activity of these drugs is the inhibition of the reuptake of serotonin, the cascade of monoamine processes in the brain connects serotonin with both norepinephrine and dopamine. Thus, the increase of availability of serotonin results in increased availability of norepinephrine and dopamine as well. The present invention provides a method for increasing the availability of serotonin, norepinephrine and dopamine, even compared to the usual increased availability caused by citalopram, fluvoxamine and paroxetine, by potentiating the action of those drugs. SUMMARY OF THE INVENTION The invention provides a method for potentiating the action of a first component chosen from the group consisting of citalopram, fluvoxamine and paroxetine in increasing the availability of serotonin, norepinephrine and dopamine in the brain, comprising administering a first component in combination with a second component chosen from the group consisting of alprenolol, WAY 100135, WAY 100635, spiperone, pindolol, (S)-UH-301, penbutolol, propranolol, tertatolol, and a compound of the formula R 1 is an optional methyl group substituted on one of the three connecting carbon atoms; R 2 is hydrogen, C 1 -C 4 alkyl, trifluoromethyl, hydroxy, (C 1 -C 4 alkyl)-O—, (C 1 -C 4 alkyl)-S(O) p —, or halo; R 3 is C 3 -C 8 cycloalkyl or a bicycloalkyl group of the formula  where a and c are independently 1-5, b is 0-5, and (a+c) is greater than 2; Z is a straight or branched C 4 -C 10 alkane, alkene, or alkyne group; (C 4 -C 8 cycloalkyl) optionally substituted with C 1 -C 4 alkyl or phenyl; a bicycloalkyl group of the formula  wherein a and c are independently 1-5, b is 0-5, and (a+c) is greater than 2; optionally phenyl substituted C 2 -C 10 alkyl where the phenyl group can be optionally substituted with R 2 as previously defined; or (C 1 -C 4 alkylidene)-T-(C 1 -C 4 alkyl), where T is —O—, —S—, —SO—, or —SO 2 —; where each G is independently a bond or C 1 -C 4 alkylidene; X is —H, —COY, —CN, or C 1 -C 4 alkyl; Y is —OH, —O-(C 1 -C 4 alkyl), or —NH 2 ; R a and R a′ are independently hydrogen or C 1 -C 3 alkyl, or when taken together with the carbon atom to which they are attached form a C 3 -C 8 cycloalkyl ring; p is 0, 1, or 2; A is —O—, —S—, —NH—, or —NCH 3 —; and m is 0, 1, 2, or 3; or a pharmaceutically acceptable salt thereof; provided that when the first component is citalopram, the second component is not (S)-UH-301 or penbutolol; and provided that when the first component is paroxetine or fluvoxamine, the second component is not pindolol. The invention also provides pharmaceutical compositions which comprise a first component in combination with one of the second component compounds named above. Further, it provides methods of treating a pathological condition which is created by or is dependent upon decreased availability of serotonin, dopamine or norepinephrine, which comprise administering to a patient in need of such treatment an adjunctive therapy comprising a first component and one of the compounds named above. Still further, the invention provides a preferred manner of carrying out the above method of adjunctive therapy, wherein the provisos above are disregarded, wherein the second component is administered in a manner which provides a substantially constant blood level of the second component, which level is sufficient to provide a substantially constant degree of potentiation of the action of the first component. Compositions adapted for carrying out the preferred manner of the invention are also provided. DESCRIPTION OF PREFERRED EMBODIMENTS In this document, all temperatures are described in degrees Celsius, and all amounts, ratios of amounts and concentrations are described in weight units unless otherwise stated. The Compounds Citalopram, 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile, is disclosed in U.S. Pat. No. 4,136,193 as a serotonin reuptake inhibitor. Its pharmacology was disclosed by Christensen et al., Eur. J. Pharmacol. 41, 153 (1977), and reports of its clinical effectiveness in depression may be found in Dufour et al., Int. Clin. Psychopharmacol. 2, 225 (1987), and Timmerman et al., ibid., 239. Fluvoxamine, 5-methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone O-(2-aminoethyl)oxime, is taught by U.S. Pat. No. 4,085,225. Scientific articles about the drug have been published by Claassen et al., Brit. J. Pharmacol. 60, 505 (1977); and De Wilde et al., J. Affective Disord. 4, 249 (1982); and Benfield et al., Drugs 32, 313 (1986). Paroxetine, trans-(−)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine, may be found in U.S. Pat. Nos. 3,912,743 and 4,007,196. Reports of the drug's activity are in Lassen, Eur. J. Pharmacol. 47, 351 (1978); Hassan et al., Brit. J. Clin. Pharmacol. 19, 705 (1985); Laursen et al., Acta Psychiat. Scand. 71, 249 (1985); and Battegay et al., Neuropsychobiology 13, 31 (1985). The first components are known to increase the availability of serotonin (5-HT), dopamine (DA) and norepinephrine (NE), and the second component drugs potentiate that valuable property. The second component drugs have in common the property of being antagonists of the serotonin 1A receptor. (S)-UH-301 ((S)-5-fluoro-8-hydroxy-2-dipropylaminotetralin) is well known to pharmacologists and pharmaceutical chemists. Hillver et al. taught its synthesis in J. Med. Chem. 33, 1541-44 (1990) and Moreau et al., Brain Res. Bull. 29, 901-04 (1992) provided considerable in vivo data about the compound. Alprenolol (1-(1-methylethyl)amino-3-[2-(2-propenyl)phenoxy]-2-propanol) was disclosed by Brandstrom et al., U.S. Pat. No. 3,466,325, which shows its preparation as Example 5. WAY 100135 (N-(t-butyl)-3-[4-(2-methoxyphenyl)piperazin-1-yl]-2-phenylpropanamide) was disclosed by Abou-Gharbia et al., U.S. Pat. No. 4,988,814, who taught that the compound has affinity for the 5-HT 1A receptor. Cliffe et al., J. Med. Chem. 36, 1509-10 (1993) showed that the compound is a 5-HT 1A antagonist. WAY 100635 (N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-(2-pyridyl)cyclohexanecarboxamide) was put in the literature by Cliffe et al., European Patent Publication 0512755, published Nov. 11, 1992. A number of papers about the compound and its activity as a 5-HT 1A antagonist were presented at the IUPHAR Satellite Meeting on Serotonin, Jul. 30, 1994, Chicago, Ill., and abstracts were published. Spiperone (8-[4-(4-fluorophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one) is a well-known compound, taught in U.S. Pat. Nos. 3,155,669 and 3,155,670. Its activity as a 5-HT 1A antagonist is shown by Middlemiss et al., Neurosci. and Biobehav. Rev. 16, 75-82 (1992). Tertatolol (8-(3-t-butylamino-2-hydroxypropyloxy)thiochroman) was disclosed by Malen et al., U.S. Pat. No. 3,960,891, which teaches it to be a blocker of cardiac beta-adrenergic receptors. Its other activities, including the presently used 5-HT 1A antagonist activity, have been discovered since the original patents appeared. Propranolol (1-isopropylamino-3-(1-naphthalenyloxy)-2-propanol) was disclosed by Crowther et al., U.S. Pat. No. 3,337,628 to be a beta-blocker like tertatolol. Again, its other properties are also well known to pharmacologists. Penbutolol (1-(t-butylamino)-2-hydroxy-3-(2-cyclopentyl-phenoxy)propane) was taught by Ruschig et al., U.S. Pat. No. 3,551,493, which describes it as a beta-blocker. Both the (−) and the (+) enantiomers of penbutolol are of interest; the (−) enantiomer is preferred for the present purpose but both enantiomers and the racemic mixture are included in the word “penbutolol” in this document. Pindolol (4-(2-hydroxy-3-isopropylaminopropoxy)indole) was disclosed by Troxler et al., U.S. Pat. No. 3,471,515, which describes this compound as well as a beta-blocker. The compound is usually administered as the racemic mixture, but the two enantiomers have been isolated and the (−) enantiomer is preferred if a single isomer product is desired in a given application. Both enantiomers and the racemic mixture are included in the word “pindolol” in this document. The compounds of formula I are taught by Beedle, et al., U.S. Pat. No. 5,013,761, the description of which is incorporated herein by reference. The synthesis and characteristics, including the 5HT 1A antagonist activity, of the compounds is shown in that patent. The particularly preferred compounds of formula I include, for example, the following individual compounds. It will be understood that the following compounds are typical of those of formula 1 but that the compounds include numerous other valuable species as shown by the previously mentioned U.S. patent. It will be further understood that, while individual salts, and in some cases, enantiomers, are mentioned below and are of particular interest, other salts, and enantiomers, diastereomers, and racemates, are likewise valuable and are included in formula I as agents for the present invention. 1-(4-indolyloxy)-3-cyclohexylamino-2-propanol, maleate salt; cis-1-(4-indolyloxy)-3-(4-phenylcyclohexyl-amino)-2-propanol, oxalate salt; 1-(4-indolyloxy)-3-(2-phenylethylamino)-2-propanol, oxalate salt; 1-(4-indolyloxy)-3-(3-phenylpropylamino)-2-propanol, oxalate salt; 1-(4-indolyloxy)-3-(4-phenylbutylamino)-2-propanol, oxalate salt; 1-(4-indolyloxy)-3-cyclopentylamino-2-propanol, maleate salt; 1-(4-indolyloxy)-3-cycloheptylamino-2-propanol; (S)-(−)-1-(4-indolyloxy)-3-cyclohexylamino-2-propanol, maleate salt; (+)-1-(4-indolyloxy)-3-cyclohexylamino-2-propanol, maleate salt; 1-(4-indolyloxy)-3-(3-methylcyclohexylamino)-2-propanol; 1-(4-indolyloxy)-3-(4-methylcyclohexylamino)-2-propanol; 1-(4-indolyloxy)-3-(5-phenylpentylamino)-2-propanol, oxalate salt; 1-(4-indolyloxy)-3-(6-phenylhexylamino)-2-propanol, oxalate salt; 1-(4-indolyloxy)-3-(2,3-dimethylcyclohexyl-amino)-2-propanol, oxalate salt; (+−)-1-(4-indolyloxy)-3-(3-pentylamino)-2-propanol; (R)-(+)-1-(4-indolyloxy)-3-cyclohexylamino-2-propanol, butanedioate salt; (R)-(−)-1-(4-indolyloxy)-3-cyclohexylamino-2-propanol, butanedioate salt; 1-(2-trifluoromethyl-4-benzimidazolyl)-3-(4-phenylbutylamino)-2-propanol; (exo)-1-(4-indolyloxy)-3-(norbornylamino)-2-propanol; (endo)-1-(4-indolyloxy)-3-(norbornylamino)-2-propanol; 1-(1-napthalenyloxy)-3-cycloheptylamino-2-propanol, oxalate salt; 1-(2-cyclopentylphenoxy)-3-cycloheptylamino-2-propanol, oxalate salt; 1-(2-cyclohexylphenoxy)-3-cyclooctylamino-2-propanol, oxalate salt; 1-(2-cycloheptylphenoxy)-3-(1,2,3-trimethyl-2-propylamino)-2-propanol, oxalate salt; and 1-(2-cyclopropylphenoxy)-3-(1,1-dimethylbutyl-amino)-2-propanol, oxalate salt. The group of the compounds of formula I wherein the group Ar is indolyl or substituted indolyl constitutes a further preferred class of 5-HT 1A antagonists; and the compounds of formula 1 wherein Z is (C 4 -C 8 cycloalkyl) optionally substituted with C 1 -C 4 alkyl or phenyl; or Z represents optionally phenyl substituted C 2 -C 10 alkyl where the phenyl group can be optionally substituted with R 2 ; constitute further particularly preferred classes of compounds for use in the present invention. All of the U.S. patents which have been mentioned above in connection with compounds used in the present invention are incorporated herein by reference. While all combinations of first component and second component compounds are useful and valuable, certain combinations are particularly valued and are preferred, as follows: citalopram/pindolol fluvoxamine/penbutolol paroxetine/penbutolol citalopram/propranolol fluvoxamine/propranolol paroxetine/propranolol paroxetine/tertatolol fluvoxamine/tertatolol citalopram/tertatolol citalopram/4-(2-hydroxy-3-cyclohexylaminopropoxy)indole fluvoxamine/4-(2-hydroxy-3-cyclohexylaminopropoxy)indole paroxetine/4-(2-hydroxy-3-cyclohexylaminopropoxy)indole It will be understood by the skilled reader that all of the compounds used in the present invention are capable of forming salts, and that the salt forms of pharmaceuticals are commonly used, often because they are more readily crystallized and purified than are the free bases. In all cases, the use of the pharmaceuticals described above as salts is contemplated in the description herein, and often is preferred, and the pharmaceutically acceptable salts of all of the compounds are included in the names of them. Administration The dosages of the drugs used in the present invention must, in the final analysis, be set by the physician in charge of the case, using knowledge of the drugs, the properties of the drugs in combination as determined in clinical trials, and the characteristics of the patient, including diseases other than that for which the physician is treating the patient. General outlines of the dosages, and some preferred dosages, can and will be provided here. Dosage guidelines for some of the drugs will first be given separately; in order to create a guideline for any desired combination, one would choose the guidelines for each of the component drugs. Citalopram: from about 5 to about 50 mg once/day; preferred, from about 10 to about 30 mg once/day; Fluvoxamine: from about 20 to about 500 mg once/day; preferred, from about 50 to about 300 mg once/day; Paroxetine: from about 5 to about 100 mg once/day; preferred, from about 50 to about 300 mg once/day. Pindolol: from about 1 to about 60 mg once-thrice/day; preferred, from about 5 to about 60 mg once-thrice/day; also preferred, from about 1 to about 10 mg twice/day; Penbutolol: from about 2 to about 80 mg once/day; preferred, from about 10 to about 80 mg once/day; also preferred, from about 2 to about 20 mg once/day; Propranolol: from about 10 to about 240 mg once-twice/day; preferred, from about 10 to about 120 mg twice/day; also preferred, from about 40 to about 240 mg once-twice/day; 4-(2-Hydroxy-3-cyclohexylaminopropoxy)indole: from about 1 to about 50 mg once-twice/day; preferred, from about 1 to about 10 mg twice/day. In more general terms, one would create a combination of the present invention by choosing a dosage of first component compound according to the spirit of the above guideline, and choosing a dosage of the second component compound in the general range of from about 1 to about 250 mg/dose. More preferred dosages, depending on the compound, would be from about 1 to about 100 mg/dose, and even more preferred dosages would be likely to be found in the range of from about 1 to about 50 mg/dose, ideally from about 1 to about 25 mg/dose. The adjunctive therapy of the present invention is carried out by administering a first component together with one of the second component compounds in any manner which provides effective levels of the two compounds in the body at the same time. All of the compounds concerned are orally available and are normally administered orally, and so oral administration of the adjunctive combination is preferred. They may be administered together, in a single dosage form, or may be administered separately. However, oral administration is not the only route or even the only preferred route. For example, transdermal administration may be very desirable for patients who are forgetful or petulant about taking oral medicine. One of the drugs may be administered by one route, such as oral, and the other may be administered by the trans-dermal, percutaneous, intravenous, intramuscular, intranasal or intrarectal route, in particular circumstances. The route of administration may be varied in any way, limited by the physical properties of the drugs and the convenience of the patient and the caregiver. It is particularly preferred, however, for the adjunctive combination to be administered as a single pharmaceutical composition, and so pharmaceutical compositions incorporating both a first component and a second component compound are important embodiments of the present invention. Such compositions may take any physical form which is pharmaceutically acceptable, but orally usable pharmaceutical compositions are particularly preferred. Such adjunctive pharmaceutical compositions contain an effective amount of each of the compounds, which effective amount is related to the daily dose of the compounds to be administered. Each adjunctive dosage unit may contain the daily doses of both compounds, or may contain a fraction of the daily doses, such as one-third of the doses. Alternatively, each dosage unit may contain the entire dose of one of the compounds, and a fraction of the dose of the other compound. In such case, the patient would daily take one of the combination dosage units, and one or more units containing only the other compound. The amounts of each drug to be contained in each dosage unit depends on the identity of the drugs chosen for the therapy, and other factors such as the indication for which the adjunctive therapy is being given. The second component compounds, taken as a class, have short lives in the body and, accordingly, provide only short periods of activity following each dose. For example, pindolol is routinely administered twice/day in the prior art, and it has been administered even more often. In the context of the present invention, it is therefore preferred to administer the second component compounds in a manner which supplies a substantially constant blood level of the second component in the body of the patient, at a sufficiently high level to provide a substantially constant degree of potentiation of the action of the first component. When the invention is carried out in this manner, the provisos in the general definition in the Summary are not operative; for example, the-combination of citalopram and (S)-UH-301 is included in the invention when this manner of administration is used. It is not intended, of course, that the present invention or any method of human treatment can provide a truly constant blood level and degree of potentiation. Biological processes always vary and prevent precisely constant results. The term “substantially constant” is used herein to refer to administration resulting in blood levels and degrees of potentiation which are sufficiently constant as to provide continuous improved efficacy over a treatment day, compared to the efficacy of the first component compound alone. Another way to consider substantially constant potentiation is by comparing the availability of serotonin, norepinephrine and dopamine in the brain of the patient. By “substantially constant” in such terms is meant a condition where the peak and the valley of availability differ by no more than about a factor of 2 over the course of a treatment day. Another way to consider “substantially constant” is a condition where the peak and valley differ by no more than about a factor of 1.5; or they differ by no more than a range of from about 1.5 to about 3. Such administration of the second component may be provided by means known to pharmaceutical scientists. For example, the total daily dosage of a second component may be formulated in a manner which provides a substantially constant flow of compound to the patient. To consider only pindolol, at least the following references teach sustained release formulations: German Patent 3632201, capsules; Swiss Patent 634990, tablets; German Patent 3237945, buccal tape; German Patent 2732335, tablets; U.S. Pat. No. 5,260,066, cryogels; European Patent Publication 361894, liposomes; Japanese Patent 84-66710, transdermal patches. Pharmaceutical scientists are acquainted in modern practice with the manners of adjusting a sustained release formulation to provide the desired rate of administration of a given compound and such formulations can be prepared by the skill of the pharmaceutical art of the compounds used as second components here. Such formulations of a second component compound may be combined in a single dosage form with the chosen first component compound. For example, a small tablet or pellets of the second component, formulated to provide constant availability of the compound, may be combined, for example in a capsule, with the first component compound. Alternatively, a transdermal patch may be prepared which has a relatively rapidly releasing area of first component, and a relatively slowly releasing area of second component. Still further, a suspension may be prepared in which the first component is present as particles of pure compound, and the particles of the second component are coated to provide sustained release in the body. In such manners, the availability of the second component may be adjusted to provide the desired substantially constant blood levels and, hence, substantially constant potentiation of the first component. Compositions so adapted for providing substantially constant potention of the first component are preferred compositions of the present invention. The inert ingredients and manner of formulation of the adjunctive pharmaceutical compositions are conventional, except for the presence of the combination of the first component and the second component compound. The usual methods of formulation used in pharmaceutical science may be used here. All of the usual types of compositions may be used, including tablets, chewable tablets, capsules, solutions, parenteral solutions, intranasal sprays or powders, troches, suppositories, transdermal patches and suspensions. In general, compositions contain from about 0.5% to about 50% of the compounds in total, depending on the desired doses and the type of composition to be used. The amount of the compounds, however, is best defined as the effective amount, that is, the amount of each compound which provides the desired dose to the patient in need of such treatment. The activity of the adjunctive combinations do not depend on the nature of the composition, so the compositions are chosen and formulated solely for convenience and economy. Any of the combinations may be formulated in any desired form of composition. Some discussion of different compositions will be provided, followed by some typical formulations. Capsules are prepared by mixing the compound with a suitable diluent and filling the proper amount of the mixture in capsules. The usual diluents include inert powdered substances such as starch of many different kinds, powdered cellulose, especially crystalline and microcrystalline cellulose, sugars such as fructose, mannitol and sucrose, grain flours and similar edible powders. Tablets are prepared by direct compression, by wet granulation, or by dry granulation. Their formulations usually incorporate diluents, binders, lubricants and disintegrators as well as the compound. Typical diluents include, for example, various types of starch, lactose, mannitol, kaolin, calcium phosphate or sulfate, inorganic salts such as sodium chloride and powdered sugar. Powdered cellulose derivatives are also useful. Typical tablet binders are substances such as starch, gelatin and sugars such as lactose, fructose, glucose and the like. Natural and synthetic gums are also convenient, including acacia, alginates, methylcellulose, polyvinylpyrrolidine and the like. Polyethylene glycol, ethylcellulose and waxes can also serve as binders. A lubricant is necessary in a tablet formulation to prevent the tablet and punches from sticking in the die. The lubricant is chosen from such slippery solids as talc, magnesium and calcium stearate, stearic acid and hydrogenated vegetable oils. Tablet disintegrators are substances which swell when wetted to break up the tablet and release the compound. They include starches, clays, celluloses, algins and gums. More particularly, corn and potato starches, methylcellulose, agar, bentonite, wood cellulose, powdered natural sponge, cation-exchange resins, alginic acid, guar gum, citrus pulp and carboxymethylcellulose, for example, may be used, as well as sodium lauryl sulfate. Enteric formulations are often used to protect an active ingredient from the strongly acid contents of the stomach. Such formulations are created by coating a solid dosage form with a film of a polymer which is insoluble in acid environments, and soluble in basic environments. Exemplary films are cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropyl methylcellulose phthalate and hydroxypropyl methylcellulose acetate succinate. Tablets are often coated with sugar as a flavor and sealant, or with film-forming protecting agents to modify the dissolution properties of the tablet. The compounds may also be formulated as chewable tablets, by using large amounts of pleasant-tasting substances such as mannitol in the formulation, as is now well-established practice. Instantly dissolving tablet-like formulations are also now frequently used to assure that the patient consumes the dosage form, and to avoid the difficulty in swallowing solid objects that bothers some patients. When it is desired to administer the combination as a suppository, the usual bases may be used. Cocoa butter is a traditional suppository base, which may be modified by addition of waxes to raise its melting point slightly. Water-miscible suppository bases comprising, particularly, polyethylene glycols of various molecular weights are in wide use, also. Transdermal patches have become popular recently. Typically they comprise a resinous composition in which the drugs will dissolve, or partially dissolve, which is held in contact with the skin by a film which protects the composition. Many patents have appeared in the field recently. Other, more complicated patch compositions are also in use, particularly those having a membrane pierced with innumerable pores through which the drugs are pumped by osmotic action. The following typical formulae are provided for the interest and information of the pharmaceutical scientist. FORMULATION 1 Hard gelatin capsules are prepared using the following ingredients: Quantity (mg/capsule) Citalopram, hydrochloride 20 mg Pindolol 30 Starch, dried 200 Magnesium stearate 10 Total 260 mg FORMULATION 2 A tablet is prepared using the ingredients below: Quantity (mg/capsule) Fluvoxamine, hydrochloride 10 (-)-Penbutolol 40 Cellulose, microcrystalline 400 Silicon dioxide, fumed 10 Stearic acid 5 Total 465 mg The components are blended and compressed to form tablets each weighing 465 mg. FORMULATION 3 An aerosol solution is prepared containing the following components: Weight Paroxetine, hydrochloride 10 (S)-UH-301 10 Ethanol 25.75 Propellant 22 70.00 (Chlorodifluoromethane) Total 115.75 The active compound is mixed with ethanol and the mixture added to a portion of the propellant 22, cooled to −30° C. and transferred to a filling device. The required amount is then fed to a stainless steel container and diluted with the remainder of the propellant. The valve units are then fitted to the container. FORMULATION 4 Tablets, each containing 80 mg of active ingredient, are made as follows: Fluvoxamine, hydrochloride 20 mg (-)-Penbutolol 60 mg Starch 45 mg Microcrystalline cellulose 35 mg Polyvinylpyrrolidone 4 mg (as 10% solution in water) Sodium carboxymethyl starch 4.5 mg Magnesium stearate 0.5 mg Talc 1 mg Total 170 mg The active ingredient, starch and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly. The aqueous solution containing polyvinyl-pyrrolidone is mixed with the resultant powder, and the mixture then is passed through a No. 14 mesh U.S. sieve. The granules so produced are dried at 50° C. and passed through a No. 18 mesh U.S. Sieve. The sodium carboxymethyl starch, magnesium stearate and talc, previously passed through a No. 60 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 170 mg. FORMULATION 5 Capsules, each containing 130 mg of active ingredient, are made as follows: Paroxetine, hydrochloride 30 mg Propranolol 100 mg Starch 59 mg Microcrystalline cellulose 59 mg Magnesium stearate 2 mg Total 250 mg The active ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No. 45 mesh U.S. sieve, and filled into hard gelatin capsules in 250 mg quantities. FORMULATION 6 Suppositories, each containing 45 mg of active ingredient, are made as follows: Citalopram, hydrochloride 5 mg Propranolol 40 mg Saturated fatty acid glycerides 2,000 mg Total 2,045 mg The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2 g capacity and allowed to cool. FORMULATION 7 Suspensions, each containing 70 mg of active ingredient per 5 ml dose, are made as follows: Fluvoxamine, racemic, hydrochloride 10 mg Propranolol 60 mg Sodium carboxymethyl cellulose 50 mg Syrup 1.25 ml Benzoic acid solution 0.10 ml Flavor q.v. Color q.v. Purified water to total 5 ml The active ingredient is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, flavor and color are diluted with a portion of the water and added, with stirring. Sufficient water is then added to produce the required volume. FORMULATION 8 An intravenous formulation may be prepared as follows: Citalopram, hydrochloride 10 mg Propranolol 20 mg Isotonic saline 1,000 ml Benefit of the Invention As stated above, the benefit of the invention is its ability to augment the increase in availability of serotonin, norepinephrine and dopamine caused by the first component compounds, resulting in improved activity in treating the various conditions described below in detail. The increase in availability of serotonin is particularly important and is a preferred aspect of the invention. Further, the invention provides a more rapid onset of action than is usually provided by treatment with the first component alone. Preferred pathological conditions to be treated by the present method of adjunctive therapy include depression, obsessive-compulsive disease and obesity. Depression in its many variations has recently become much more visible to the general public than it has previously been. It is now recognized as an extremely damaging disorder, and one that afflicts a surprisingly large fraction of the population. Suicide is the most extreme symptom of depression, but millions of people, not quite so drastically afflicted, live in misery and partial or complete uselessness, and afflict their families as well by their affliction. The introduction of fluoxetine was a breakthrough in the treatment of depression, and depressives are now much more likely to be diagnosed and treated than they were only a decade ago. The three first component compounds herein are in use for the treatment of depression. Depression is often associated with other diseases and conditions, or caused by such other conditions. For example, it is associated with Parkinson's disease; with HIV; with Alzheimer's disease; and with abuse of anabolic steroids. Depression may also be associated with abuse of any substance, or may be associated with behavioral problems resulting from or occurring in combination with head injuries, mental retardation or stroke. Depression in all its variations is a preferred target of treatment with the present adjunctive therapy method and compositions. Obsessive-compulsive disease appears in a great variety of degrees and symptoms, generally linked by the patient's uncontrollable urge to perform needless, ritualistic acts. Acts of acquiring, ordering, cleansing and the like, beyond any rational need or rationale, are the outward characteristic of the disease. A badly afflicted patient may be unable to do anything but carry out the rituals required by the disease. Obesity is common in the populations of industrial and developing countries. It has been found that serotonin reuptake inhibitors will enable an obese patient to lose weight, with the resulting benefit to the patient's circulation and heart condition, as well as general well being and energy. Urinary incontinence is classified generally as stress or urge incontinence, depending on whether its root cause is the inability of the sphincter muscles to keep control, or the overactivity of the bladder muscles. The present invention is useful for treating many other diseases, disorders and conditions as well, as set out below. In many cases, the diseases to be mentioned here are classified in the International Classification of Diseases, 9th Edition (ICD), or in the Diagnostic and Statistical Manual of Mental Disorders, 3rd Version Revised, published by the American Psychiatric Association (DSM). In such cases, the ICD or DSM code numbers are supplied below for the convenience of the reader. depression, ICD 296.2 & 296.3, DSM 296, 294.80, 293.81, 293.82, 293.83, 310.10, 318.00, 317.00 migraine pain, particularly neuropathic pain bulimia, ICD 307.51, DSM 307.51 premenstrual syndrome or late luteal phase syndrome, DSM 307.90 alcoholism, ICD 305.0, DSM 305.00 & 303.90 tobacco abuse, ICD 305.1, DSM 305.10 & 292.00 panic disorder, ICD 300.01, DSM 300.01 & 300.21 anxiety, ICD 300.02, DSM 300.00 post-traumatic syndrome, DSM 309.89 memory loss, DSM 294.00 dementia of aging, ICD 290 social phobia, ICD 300.23, DSM 300.23 attention deficit hyperactivity disorder, ICD 314.0 disruptive behavior disorders, ICD 312 impulse control disorders, ICD 312, DSM 312.39 & 312.34 borderline personality disorder, ICD 301.83, DSM 301.83 chronic fatigue syndrome premature ejaculation, DSM 302.75 erectile difficulty, DSM 302.72 anorexia nervosa, ICD 307.1, DSM 307.10 disorders of sleep, ICD 307.4 autism mutism trichotillomania Experimental Results The 5-HT 1a antagonist WAY 100635 has been tested in conscious experimental animals adapted to dark-cycle (lights off 9:00 AM to 9:00 PM) to demonstrate that 5-HT 1a antagonist activity alone is insufficient to increase extracellular serotonin levels. Microdialysis Assays of Monoamines Male Sprague-Dawley rats (Charles Rivers) were housed under a reversed light period (lights off 9:00 AM). Rats were adapted to the reverse light period room for at least 14 days prior to implantation. Rats weighing 270-300 grams were surgically implanted with microdialysis probes under chloral hydrate/pentobarbital anesthesia (170 and 36 mg/kg i.p. in 30% propylene glycol, 14% ethanol) (Perry and Fuller, Effect of fluoxetine on serotonin and dopamine concentration in rat hypothalamus after administration of fluoxetine plus L-5-hydroxytrypto-phan, Life Sci., 50, 1683-90 (1992)). A David Kopf stereotaxic instrument was used to implant the microdialysis probe unilaterally in the hypothalamus at coordinates rostral −1.9 mm, lateral −1.5 mm, and ventral −9.0 mm from bregma (Paxinos and Watson, 1986). A subcutaneous cannula (PE-20 tubing, 10 cm long) was inserted between the skin and neck muscle. The other end of the tubing was cemented in place, along with the probe, through the top of the headstage. After a 48 hour recovery period, rats were placed in a large plastic bowl with a mounted liquid swivel system (CMA/120 system for freely moving animals, Bioanalytical Systems, West Lafayette, Ind.). Filtered artificial cerebrospinal fluid (CSF) (150 mM NaCl, 3.0 mM KCl, 1.7 mM CaCl 2 , and 0.9 mM MgCl 2 pH=6.0) was perfused through the probe at a rate of 2.0 μl/min. The output dialysate line was fitted to a tenport HPLC valve with a 20 μL loop. At the end of each 15 minute sampling period, dialysate collected in the loop was passed through a guard column (2 mm, C-18, Keystone Scientific), then on to an analytical column (BDS-Hypersil C-18, 3 μm, 2×150 mm, Keystone Scientific). The method used to measure monoamines was as described by Perry and Fuller (1992). The dialysate collected in the 20 μL sample loop was injected onto the HPLC column with a mobile phase containing 75 mM sodium phosphate, 0.5 mM ethylenediaminetetraacetic acid, 350 mg/L 1-octanesulfonic acid, 9% acetonitrile, and 0.9% tetrahydrofuran, pH 3.0. The mobile phase was delivered at a flow rate of 0.2 mL/min. A dual electrode coupled with an electrochemical detector with two potentiostat boards (EG&G, Model 400) were used to detect 5-HT. Data were collected and analyzed with an EZ CHROM™ data chromatography system running on a COMPAQ™ 486/33 computer. Monoamine concentrations were calculated by comparing peak heights using 5 pMol/mL standards. Basal levels were measured for at least 60 minutes prior to drug administration. Fifteen minutes prior to beginning continuous subcutaneous infusion of WAY100635, a small amount (0.02 mL) of distilled water was injected into the subcutaneous cannula to clear it. WAY100635 was dissolved in distilled water, and the pH was adjusted to 4.0 with sodium hydroxide (1N). The solution was delivered at a rate of 2.5 μL/min through the subcutaneous cannula, which provided the administration of WAY100635 at a rate of 1 mg/kg/hr. Evaluation and Statistical Analyses Extracellular levels of 5-HT in microdialysates were calculated by comparing peak heights with those of a 5 pMol/ml standard. The mean value of the four samples immediately preceding drug administration served as the basal level for each experiment and data was converted to percent of basal. Paired t-tests were used to compare the mean of the basal values from the time point immediately preceding drug administration to those of each time point thereafter. In this test, WAY 100635 was continuously infused subcutaneously (1 mg/kg/hr), beginning 90 minutes after the start of the experiment. The results are shown below as percent of baseline of serotonin at various times after the start of the experiment. Each data point reported here represents the average value for from 5-7 test animals as by the variable “N”. TIME (min.) % 5-HT Standard Error N 15 102.8 4.4 5 30 108.0 3.8 7 45 104.3 3.8 7 60 103.1 5.4 7 75 78.0 4.3 7 90 84.0 7.9 6 105 91.9 6.8 7 120 91.1 10.5 7 135 104.6 6.1 7 150 100.3 5.4 7 165 111.1 17.4 7 180 116.4 10.4 7 These results clearly demonstrate that the administration of a 5-HT 1a antagonist alone has no effect on the levels of extracellular serotonin.

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (20)

    Publication numberPublication dateAssigneeTitle
    EP-0512755-A2November 11, 1992JOHN WYETH & BROTHER LIMITEDDérivés de pipérazine
    US-3155669-ANovember 03, 1964Res Lab Dr C Janssen N V2, 4, 8-triaza-spiro (4, 5) dec-2-enes
    US-3155670-ANovember 03, 1964Res Lab Dr C Janssen N V1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes
    US-3337628-AAugust 22, 1967Ici Ltd3-naphthyloxy-2-hydroxypropylamines
    US-3466325-ASeptember 09, 1969Haessle Ab1-(ortho-alkenyl phenoxy) - 2-hydroxy-3-isopropylaminopropanes and the salts thereof
    US-3471515-AOctober 07, 1969Sandoz Ag(2-hydroxy-3-substituted aminopropoxy)indoles
    US-3551493-ADecember 29, 1970Hoechst AgAlkyl-and cycloalkyl-amino-propanol-cyclopentyl- and cyclopentenyl-phenol ethers
    US-3960891-AJune 01, 1976Science-Union Et CieThiochroman compounds
    US-4314081-AFebruary 02, 1982Eli Lilly And CompanyArloxyphenylpropylamines
    US-4478836-AOctober 23, 1984Pierre Fabre S.A.1-Aryl 2-aminomethyl cyclopropane carboxyamide (Z) derivatives and their use as useful drugs in the treatment of disturbances of the central nervous system
    US-4761501-AAugust 02, 1988American Home Products CorporationSubstituted phenylacetamides
    US-4956388-ASeptember 11, 1990Eli Lilly And Company3-aryloxy-3-substituted propanamines
    US-4988814-AJanuary 29, 1991American Home Products Corp., John Wyeth & Bro.Tertiary alkyl functionalized piperazine derivatives
    US-5013761-AMay 07, 1991Eli Lilly And CompanySerotonin antagonists
    US-5532244-AJuly 02, 1996Eli Lilly And CompanyPotentiation of drug response
    US-5532250-AJuly 02, 1996Eli Lilly And CompanyPotentiation of drug response
    US-5532264-AJuly 02, 1996Eli Lilly And CompanyPotentiation of drug response
    US-5532268-AJuly 02, 1996Eli Lilly And CompanyPotentiation of drug response
    US-5538992-AJuly 23, 1996Eli Lilly And CompanyPotentiation of drug response
    US-5552429-ASeptember 03, 1996Eli Lilly And CompanyPotentiation of drug response

NO-Patent Citations (23)

    Title
    Abstract book, 3rd IUPHAR Satellite Meeting on Serotonin, Jul. 30, 1994, Chicago, pp. 25, 46, 69, 91-94.
    Arborelius, et al., Arch. Pharmacol. (1996) 353:630-640.
    Artigas, et al., Arch. Gen. Psychiarty, 51, 248-251 (1994).
    Artigas, TiPs, 14, 262 (1993).
    Baumann, et al., Arch. Pharmacol., (1981), 317, pp. 36-43.
    Bel et al., Proceedings of the 6th International Conference On In Vivo Methods, Sep. 17-20, 1994, pp. 209-210.
    Cardoni, Hosp. Formul., 27, 445-463 (1992).
    Cliffe, et al., J. Med. Chem., 36, 1509-1510 (1993).
    Donovan, et al., Current Therapeutic Research, 54, (3) (1993).
    Fuller, Life Sciences, 55, 163-167 (1994).
    Gurling, et al., 6th International Conference on in vivo Methods, 211-212.
    Hillver, et al, J. Med. Chem., 33, 1541-1544 (1990).
    Hjorth, et al., European Journal of Pharmcology; 260 (1994), pp. 251-255.
    Hjorth, Journal of Neurochemistry, 60, 776-779 (1993).
    Invernizzi, et al., Brain Research, 584, 322-324 (1992).
    Jacobsen, J. Clin. Psychiatry, 52, 217-220 (1991).
    Middlemiss, et al., Neuroscience & Biobehavioral Reviews, 16, 75-82 (1992).
    Moreau, et al., Brain Research Bulletin, 29, 901-904 (1992).
    Moret, et al., Neuropharmacology, 24, 1211-1219 (1985).
    Nomikos, et al., European Journal of Pharmacology; 216(1992) 373-378.
    Nyth, et al., Acta Psychiatr Scand, 86, 138-145 (1992).
    Robertson, et al., J. Med. Chem., 31, 1412-1417 (1988).
    Tang, et al., Psychiatry Research, 33, 101-106 (1990).

Cited By (76)

    Publication numberPublication dateAssigneeTitle
    US-2004198811-A1October 07, 2004H. Lundbeck A/SUse of enantiomeric pure escitalopram
    US-2006287333-A1December 21, 2006WyethSerotonergic agents for treating sexual dysfunction
    US-2007042034-A1February 22, 2007Myriad Genetics, IncorporatedHigh drug load formulations and dosage forms
    US-8580313-B2November 12, 2013Aptalis Pharma LimitedFexofenadine microcapsules and compositions containing them
    US-2004010006-A1January 15, 2004WyethAntidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-1,3-diazacyclopenta[a]naphthalene
    US-2008033045-A1February 07, 2008Myriad Genetics, IncorporatedTreatment of psychiatric disorders
    US-2007253905-A1November 01, 2007Mayo Foundation For Medical Education, The Regents Of The University Of CaliforniaAbeta42 LOWERING AGENTS
    US-2004198809-A1October 07, 2004Connie Sanchez, Arne MorkUse of enantiomeric pure escitalopram
    US-9233105-B2January 12, 2016Adare Pharmaceuticals S.R.L.Fexofenadine microcapsules and compositions containing them
    US-9539242-B2January 10, 2017University Of Virginia Patent FoundationMolecular genetic approach to treatment and diagnosis of alcohol and drug dependence
    US-2006287335-A1December 21, 2006WyethSerotonergic agents for treating sexual dysfunction
    US-8753815-B2June 17, 2014University Of Virginia Patent FoundationMolecular genetic approach to treatment and diagnosis of alcohol and drug dependence
    US-8956650-B2February 17, 2015Kyowa Hakko Kirin Co., Ltd.Intrabuccally rapidly disintegrating tablet and a production method of the tablets
    US-9161919-B2October 20, 2015Adare Pharmaceuticals, Inc.Timed, pulsatile release systems
    US-2007232656-A1October 04, 2007Myriad Genetics, IncorporatedPharmaceutical Composition And Method For Treating Neurodegenerative Disorders
    US-8367111-B2February 05, 2013Aptalis Pharmatech, Inc.Extended release dosage forms of propranolol hydrochloride
    US-7265151-B2September 04, 2007H. Lundbeck A/STreatment of neurotic disorders
    WO-0236114-A1May 10, 2002Respiratorius AbComposition comprenant les antagonistes des recepteurs de serotonine 5 ht-2 et 5 ht-3
    US-7718646-B2May 18, 2010Sanofi-AventisCyclohexyl(alkyl)propanolamines, preparation method and pharmaceutical compositions containing same
    US-8697361-B2April 15, 2014University Of Virginia Patent FoundationSerotonin transporter gene and treatment of alcoholism
    US-2010076006-A1March 25, 2010University Of Virginia Patent FoundationTopiramate Plus Naltrexone for the Treatment of Addictive Disorders
    US-2002086899-A1July 04, 2002H. Lundbeck A/STreatment of neurotic disorders
    US-7271194-B2September 18, 2007H. Lundbeck A/STreatment of neurotic disorders
    US-7816362-B2October 19, 2010Wyeth LlcSerotonergic agents
    US-2007027162-A1February 01, 2007WyethCrystalline and amorphous 4-cyano-N-{(2R)-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin -1-yl]-propyl}-N-pyridin-2-yl-benzamide hydrochloride
    WO-2014209991-A1December 31, 2014The Johns Hopkins UniversityMethods for reducing anxiety and impulsivity in subjects initiating treatment with serotonin reuptake inhibitors
    US-2007232672-A1October 04, 2007Myriad Genetics, IncorporatedPharmaceutical Composition And Method For Treating Neurodegenerative Disorders
    US-2004029957-A1February 12, 2004H. Lundbeck A/STreatment of neurotic disorders
    US-6663888-B2December 16, 2003Eurand Pharmaceuticals Ltd.Pulsatile release histamine H2 antagonist dosage form
    US-2009192311-A1July 30, 2009Browne Eric N C, Michel Bernatchez, Mark Lankau, Abdolsamad Tadayon, Hadfield Anthony FCrystalline and amorphous 4-cyano-n--n-pyridin-2-yl-benzamide hydrochloride
    US-2007293538-A1December 20, 2007Myriad Genetics, IncorporatedPharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
    US-2004192765-A1September 30, 2004H. Lundbeck A/SUse of enantiomeric pure escitalopram
    US-9358214-B2June 07, 2016Adare Pharmaceuticals, Inc.Timed, sustained release systems for propranolol
    US-2006078614-A1April 13, 2006Venkatesh Gopi MTaste-masked pharmaceutical compositions
    US-6927226-B2August 09, 2005WyethAntidepressant azaheterocyclymethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-1,3-diazacyclopenta[a]naphthalene
    US-2008261949-A1October 23, 2008Sanofi-AventisCyclohexyl(alkyl)propanolamines, preparation method and pharmaceutical compositions containing same
    US-9884014-B2February 06, 2018Adare Pharmaceuticals, Inc.Taste-masked pharmaceutical compositions
    US-2011065628-A1March 17, 2011University Of Virginia Patent FoundationMedication Combinations for the Treatment of Alcoholism and Drug Addiction
    US-6960613-B2November 01, 2005H. Lundbeck A/STreatment of neurotic disorders
    US-2004192764-A1September 30, 2004H. Lundbeck A/SUse of enantiomeric pure escitalopram
    US-2004192766-A1September 30, 2004H. Lundbeck A/SUse of enantiomeric pure escitalopram
    US-2009263480-A1October 22, 2009Jin-Wang Lai, Ken Kangyi Qian, Venkatesh Gopi MTaste-masked pharmaceutical compositions prepared by coacervation
    EP-2124909-A4March 31, 2010Univ VirginiaKombinierte wirkungen von topiramat und ondansetron auf den alkoholgenuss
    US-2005288375-A1December 29, 2005Myriad Genetics, IncorporatedMethod and composition for treating neurodegenerative disorders
    US-6500454-B1December 31, 2002Eurand Pharmaceuticals Ltd.Timed, sustained release systems for propranolol
    US-2005025824-A1February 03, 2005Eurand Pharmaceuticals Ltd.Pulsatile release histamine H2 antagonist dosage form
    US-9161918-B2October 20, 2015Adare Pharmaceuticals, Inc.Timed, pulsatile release systems
    EP-2124909-A2December 02, 2009University Of Virginia Patent FoundationKombinierte wirkungen von topiramat und ondansetron auf den alkoholgenuss
    US-2004029956-A1February 12, 2004H. Lundbeck A/STreatment of neurotic disorders
    US-7419974-B2September 02, 2008Sanofi-AventisCyclohexyl(alkyl)propanolamines, preparation method and pharmaceutical compositions containing same
    US-2005252144-A1November 17, 2005Macdonald Robert A, Dawson William BVeneers for walls, retaining walls and the like
    US-2009215794-A1August 27, 2009WyethSerotonergic agents
    US-7425558-B2September 16, 2008WyethSerotonergic agents for treating sexual dysfunction
    US-2010041689-A1February 18, 2010University Of Virginia Patent FoundationCombined Effects of Topiramate and Ondansetron on Alcohol Consumption
    US-9566249-B2February 14, 2017Adare Pharmaceuticals, Inc.Timed, pulsatile release systems
    US-2008070925-A1March 20, 2008Sukoff Rizzo Stacey J, Rosenzweig-Lipson Sharon J, Childers Wayne E, Michael Kelly, Schechter Lee ESerotonergic agents for treating sexual dysfunction
    US-2008004338-A1January 03, 2008H. Lundbeck A/SUse of enantiomeric pure escitalopram
    US-2004198810-A1October 07, 2004H. Lundbeck A/SUse of enantiomeric pure escitalopram
    US-2003157173-A1August 21, 2003Percel Phillip J., Vishnupad Krishna S., Venkatesh Gopi M.Timed, sustained release systems for propranolol
    US-2005042284-A1February 24, 2005Myriad Genetics, IncorporatedPharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
    US-8357396-B2January 22, 2013Kyowa Hakko Kirin Co., Ltd.Intrabuccally rapidly disintegrating tablet and a production method of the tablets
    US-2006057199-A1March 16, 2006Venkatesh Gopi M, Harmon Troy M, John TaylorOrally disintegrating tablets of atomoxetine
    US-8747895-B2June 10, 2014Aptalis Pharmatech, Inc.Orally disintegrating tablets of atomoxetine
    US-2005101665-A1May 12, 2005H. Lundbeck A/STreatment of neurotic disorders
    US-2004029958-A1February 12, 2004H. Lundbeck A/STreatment of neurotic disorders
    US-2011112159-A1May 12, 2011University Of Virginia Patent FoundationSerotonin transporter gene and treament of alcoholism
    US-2007015745-A1January 18, 2007Sanofi-AventisCyclohexyl(alkyl)propanolamines, Preparation Method and Pharmaceutical Compositions Containing Same
    US-8945618-B2February 03, 2015Kyowa Hakko Kirin Co., Ltd.Intrabuccally rapidly disintegrating tablet and a production method of the tablets
    US-2009176808-A1July 09, 2009H. Lundbeck A/Scombination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist
    US-7388031-B2June 17, 2008Sanofi-AventisCyclohexyl(alkyl)-propanolamines, preparation method and pharmaceutical compositions containing same
    US-2006223824-A1October 05, 2006WyethSerotonergic agents
    US-2008317846-A1December 25, 2008Eurand America, Inc.Pulsatile release histamine H2 antagonist dosage form
    US-9040086-B2May 26, 2015Aptalis Pharmatech, Inc.Timed, sustained release systems for propranolol
    US-2006269607-A1November 30, 2006Eurand, Inc.Timed, sustained release systems for propranolol
    US-9579293-B2February 28, 2017Adare Pharmaceuticals, Inc.Timed, pulsatile release systems